AR106133A1 - Métodos para el tratamiento de la epilepsia - Google Patents
Métodos para el tratamiento de la epilepsiaInfo
- Publication number
- AR106133A1 AR106133A1 ARP160102914A ARP160102914A AR106133A1 AR 106133 A1 AR106133 A1 AR 106133A1 AR P160102914 A ARP160102914 A AR P160102914A AR P160102914 A ARP160102914 A AR P160102914A AR 106133 A1 AR106133 A1 AR 106133A1
- Authority
- AR
- Argentina
- Prior art keywords
- epilepsy
- treatment
- methods
- seizures
- activators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Métodos para el tratamiento de convulsiones y de la epilepsia con activadores del receptor de FGF21.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562222983P | 2015-09-24 | 2015-09-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR106133A1 true AR106133A1 (es) | 2017-12-13 |
Family
ID=57121530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160102914A AR106133A1 (es) | 2015-09-24 | 2016-09-23 | Métodos para el tratamiento de la epilepsia |
Country Status (12)
Country | Link |
---|---|
US (2) | US20180340028A1 (es) |
EP (1) | EP3353211A1 (es) |
JP (1) | JP6903640B2 (es) |
KR (1) | KR20180056657A (es) |
CN (1) | CN108026175A (es) |
AR (1) | AR106133A1 (es) |
AU (1) | AU2016326689A1 (es) |
CA (1) | CA2997290A1 (es) |
HK (1) | HK1252996A1 (es) |
IL (1) | IL257908A (es) |
MX (1) | MX2018003536A (es) |
WO (1) | WO2017053842A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113683705A (zh) | 2011-07-01 | 2021-11-23 | 恩格姆生物制药公司 | 用于代谢病症和疾病治疗的组合物、应用和方法 |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
CA2892152A1 (en) | 2012-11-28 | 2014-06-05 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
CN108888757A (zh) | 2012-12-27 | 2018-11-27 | 恩格姆生物制药公司 | 用于调节胆汁酸体内稳态及治疗胆汁酸紊乱和疾病的方法 |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
WO2015195509A2 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
WO2016073855A1 (en) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
CA3003616C (en) | 2015-11-09 | 2020-07-28 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
WO2018039557A1 (en) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US20040229292A1 (en) * | 2002-11-26 | 2004-11-18 | Sebastiano Cavallaro | Use of FGF-18 in the diagnosis and treatment of memory disorders |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
CA2782814A1 (en) | 2009-12-02 | 2011-06-09 | Amgen Inc. | Binding proteins that bind to human fgfr1c, human .beta.-klotho and both human fgfr1c and human .beta.-klotho |
UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
AU2011239689A1 (en) | 2010-04-15 | 2012-11-08 | Amgen Inc. | Human FGF receptor and beta-Klotho binding proteins |
JP6069198B2 (ja) * | 2010-07-20 | 2017-02-01 | ノヴォ ノルディスク アー/エス | N末端が修飾されたfgf21化合物 |
DK2710035T3 (en) | 2011-05-16 | 2017-06-19 | Hoffmann La Roche | FGFR1 agonists and methods of use |
US9574002B2 (en) | 2011-06-06 | 2017-02-21 | Amgen Inc. | Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor |
TWI728373B (zh) | 2013-12-23 | 2021-05-21 | 美商建南德克公司 | 抗體及使用方法 |
SG11201606018UA (en) | 2014-01-24 | 2016-08-30 | Ngm Biopharmaceuticals Inc | Binding proteins and methods of use thereof |
-
2016
- 2016-09-23 AR ARP160102914A patent/AR106133A1/es unknown
- 2016-09-23 AU AU2016326689A patent/AU2016326689A1/en not_active Abandoned
- 2016-09-23 CA CA2997290A patent/CA2997290A1/en not_active Abandoned
- 2016-09-23 CN CN201680050997.9A patent/CN108026175A/zh active Pending
- 2016-09-23 MX MX2018003536A patent/MX2018003536A/es unknown
- 2016-09-23 KR KR1020187007984A patent/KR20180056657A/ko not_active Application Discontinuation
- 2016-09-23 JP JP2018515127A patent/JP6903640B2/ja active Active
- 2016-09-23 EP EP16778958.5A patent/EP3353211A1/en not_active Withdrawn
- 2016-09-23 WO PCT/US2016/053506 patent/WO2017053842A1/en active Application Filing
-
2018
- 2018-03-06 IL IL257908A patent/IL257908A/en unknown
- 2018-03-20 US US15/926,149 patent/US20180340028A1/en not_active Abandoned
- 2018-09-26 HK HK18112356.3A patent/HK1252996A1/zh unknown
-
2020
- 2020-08-05 US US16/986,068 patent/US20200362042A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2018531927A (ja) | 2018-11-01 |
JP6903640B2 (ja) | 2021-07-14 |
MX2018003536A (es) | 2018-08-01 |
HK1252996A1 (zh) | 2019-06-06 |
AU2016326689A1 (en) | 2018-03-22 |
US20180340028A1 (en) | 2018-11-29 |
KR20180056657A (ko) | 2018-05-29 |
IL257908A (en) | 2018-05-31 |
WO2017053842A1 (en) | 2017-03-30 |
CN108026175A (zh) | 2018-05-11 |
EP3353211A1 (en) | 2018-08-01 |
CA2997290A1 (en) | 2017-03-30 |
US20200362042A1 (en) | 2020-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR106133A1 (es) | Métodos para el tratamiento de la epilepsia | |
DOP2017000124A (es) | Agonistas parciales del receptor de insulina | |
CL2019002304A1 (es) | Compuestos para el tratamiento del cáncer. | |
ECSP17073743A (es) | Moduladores de k-ras | |
ES2769863T8 (es) | 7-hidroxi-cannabidivarín (7-OH-CBDV) para usar en el tratamiento de la epilepsia | |
ECSP18008905A (es) | Tricíclicos sustituidos y método para usarlos. | |
CY1123065T1 (el) | Ανασυνδυασμενα προβιοτικα βακτηριδια | |
CL2018003123A1 (es) | Terapia de combinación para el tratamiento del cáncer | |
AU362319S (en) | Pet treat | |
BR112018006696A2 (pt) | métodos e sistemas para obter óleo a partir de uma composição de vinhoto | |
BR112017007160A2 (pt) | sistemas de catalisador de fosfinimida de titânio e de iminoimidazolidida de titânio com suportes de ativador. | |
BR112018005499A2 (pt) | métodos de tratamento de pressão intraocular com ativadores de tie-2. | |
CL2020000655A1 (es) | Tratamiento mejorado de dermatitis atópica con tradipitant. | |
DK3572405T3 (da) | Benzoimidazol-1,2-yl-amider som kv7-kanalaktivatorer | |
BR112016020381A2 (pt) | sistemas e métodos para liberação de drogas para tratamento do câncer de bexiga com gencitabina. | |
CL2017000087A1 (es) | Un proceso novedoso para la purificación de rhu-gcsf | |
UY36286A (es) | Tratamientos médicos basados en anamorelina | |
AR100231A1 (es) | Composiciones para el cuidado de las telas que comprenden polímeros de poliuretano, poliurea y/o poliuretanourea | |
CR20150640S (es) | Aparato para peinar el cabello | |
GB201420141D0 (en) | Retractor with improved light source, and light source for an improved retractor | |
CL2018000941A1 (es) | Regulación del uso de nitrógeno | |
BR112016028614A2 (pt) | novos agonistas de ep4 como compostos terapêuticos | |
ES1149359Y (es) | Dispositivo para el control, supervision y buena praxis de la actividad fisica del ser humano | |
BR112015019445A2 (pt) | método para realizar uma construção têxtil de proteção balística, construção têxtil de proteção balística feita por um método e produto de proteção balística | |
ES1178759Y (es) | Dispositivo para el tratamiento de la epilepsia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |